Last Review Date: 04/07/2025

Date of Origin: 01/01/2012

Dates Reviewed: 12/2011, 02/2013, 02/2014, 12/2014, 10/2015, 10/2016, 10/2017, 10/2018, 02/2019, 02/2020, 02/2021, 02/2022, 04/2022, 02/2023, 02/2024, 04/2025

1. Length of Authorization

Coverage will be provided for 12 months and may be renewed.

2. Dosing Limits

    Max Units (per dose and over time) [HCPCS Unit]:

• 240 billable units every 28 days

3. Initial Approval Criteria ^1,4,5,7,9,10

Coverage is provided in the following conditions:

• Patient is at least 16 months of age; AND
• Documented baseline age-appropriate values for one or more of the following have been obtained:
  • Patients 5 years of age or greater: 6-minute walk test (6MWT), percent predicted forced vital capacity (FVC), joint range of motion, left ventricular hypertrophy, growth, quality of life (CHAQ/HAQ/MPS HAQ), and/or urinary glycosaminoglycan (uGAG); OR
  • Patients 16 months to less than 5 years of age: spleen volume, liver volume, FVC, 6-MWT, and/or urinary glycosaminoglycan (uGAG); AND

NOTE: For very young patients in which FVC or 6-MWT are not suitable for measuring, requests will be reviewed on a case-by case basis.

Universal Criteria ^1,11-13

• Therapy is being used to treat non-central nervous system manifestations of the disease and patient does not have severe, irreversible cognitive impairment; AND

NOTE: Requests for continued therapy in patients with severe, irreversible cognitive impairment will be reviewed on a case-by case basis.

Hunter syndrome (Mucopolysaccharidosis II; MPS II) † Ф ^1,5

• Patient has a definitive diagnosis of MPS II as confirmed by one of the following:
  • Deficient or absent iduronate 2-sulfatase (I2S) enzyme activity in white cells, fibroblasts, or plasma in the presence of normal activity of at least one other sulfatase; OR
  • Detection of pathogenic mutations in the IDS gene by molecular genetic testing

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Ф Orphan Drug

4. Renewal Criteria ^1,4,5,7,9,10

Coverage may be renewed based on the following criteria:

• Patient continues to meet the universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; AND
• Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: severe hypersensitivity reactions including anaphylaxis, antibody development and serious adverse reactions in Hunter Syndrome patients with severe genetic mutations, acute respiratory complications, acute cardiorespiratory failure, etc.; AND
• Patient has demonstrated a beneficial response to therapy compared to pretreatment age-appropriate baseline values in one or more of the following:
  • Patients 5 years of age or greater: stabilization or improvement in percent predicted FVC and/or 6-MWT, increased joint range of motion, decreased left ventricular hypertrophy, improved growth, improved quality of life (clinically meaningful change in the CHAQ/HAQ/MPS HAQ disability index), and/or reduction in uGAG levels; OR
  • Patients 16 months to less than 5 years of age: reductions in spleen and/or liver volume, stabilization/improvement in FVC and/or 6-MWT, and/or reduction in uGAG levels

5. Dosage/Administration ¹

6. Billing Code/Availability Information

HCPCS Code:

• J1743 – Injection, idursulfase, 1 mg; 1 mg = 1 billable unit

NDC:

• Elaprase 6 mg/3 mL single-use vial for injection: 54092-0700-xx

7. References

1. Elaprase [package insert]. Lexington, MA; Takeda Pharmaceuticals U.S.A., Inc,; September 2021. Accessed February 2025.
2. Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008 Mar;167(3):267-77. Epub 2007 Nov 23.
3. Scarpa M, Almássy Z, Beck M, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis. 2011 Nov 7;6:72. doi: 10.1186/1750-1172-6-72.
4. Muenzer J, Bodamer O, Burton B, et al. The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus. Eur J Pediatr. 2012 Jan;171(1):181-8.
5. Scarpa M, Lampe C. Mucopolysaccharidosis Type II. 2007 Nov 6 [Updated 2025 Jan 16]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1274/. Accessed February 2025.
6. Burrow T, Leslie ND. Review of the use of idursulfase in the treatment of mucopolysaccharidosis II. Biologics. 2008 Jun; 2(2): 311–320.
7. Giugliani R, Villareal MLS, Valdez CAA, et al. Guidelines for diagnosis and treatment of Hunter Syndrome for clinicians in Latin America.  Genet Mol Biol. 2014 Jun; 37(2): 315–329.
8. Burton BK, Giugliani R. Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls. Eur J Pediatr 2012; 171:631.
9. Muenzer J, Wraith J, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8, 465–473 (2006) doi:10.1097/01.gim.0000232477.37660.fb
10. Muenzer J, Beck M, Eng CM, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011 Feb;13(2):95-101. doi: 10.1097/GIM.0b013e3181fea459.
11. Żuber Z, Kieć-Wilk B, Kałużny Ł, Wierzba J, Tylki-Szymańska A. Diagnosis and Management of Mucopolysaccharidosis Type II (Hunter Syndrome) in Poland. Biomedicines. 2023 Jun 8;11(6):1668. doi: 10.3390/biomedicines11061668.
12. Zhou J, Lin J, Leung WT, Wang L. A basic understanding of mucopolysaccharidosis: Incidence, clinical features, diagnosis, and management. Intractable Rare Dis Res. 2020 Feb;9(1):1-9. doi: 10.5582/irdr.2020.01011.
13. Shapiro EG, Eisengart JB. The natural history of neurocognition in MPS disorders: A review. Mol Genet Metab. 2021 May;133(1):8-34. doi: 10.1016/j.ymgme.2021.03.002. Epub 2021 Mar 11. PMID: 33741271.

Appendix 1 – Covered Diagnosis Codes

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: https://www.cms.gov/medicare-coverage-database/search.aspx. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A